Evidence map›Paper›PMID 40632976›Full record

ArticleJCO precision oncology2025

Germline

Pamela L Brock, Morgan Webster, Sandya Liyanarachchi, Lindsey Byrne, Dale J Hedges, Pat Gulhati, J Kevin Hicks, Carlos H F Chan, Kenan Onel, Leigh Anne Stout and 8 more

Abstract read
In one paragraph

Article in JCO precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Pamela L BrockDivision of Human Genetics, The Ohio State University College of Medicine, Comprehensive Cancer Center, Columbus, OH.ORCID 0000-0002-1549-5363
Morgan WebsterMaternal Fetal Medicine, Legacy Health, Portland, OR.
Sandya LiyanarachchiDepartment of Molecular Medicine and Therapeutics, The Ohio State University Comprehensive Cancer Center, Columbus, OH.ORCID 0000-0002-1857-5246
Lindsey ByrneDivision of Human Genetics, The Ohio State University College of Medicine, Comprehensive Cancer Center, Columbus, OH.ORCID 0000-0001-7131-5331
Dale J Hedges
Pat GulhatiDepartment of Medical Oncology, Rutgers Cancer Institute, New Brunswick, NJ.ORCID 0000-0003-2625-313X
J Kevin HicksDepartment of Pathology, Moffitt Cancer Center, Tampa, FL.ORCID 0000-0003-2314-0164
Carlos H F ChanHolden Comprehensive Cancer Center, University of Iowa Health Care, Iowa City, IA.ORCID 0000-0003-3656-2470
Kenan OnelRoswell Park Comprehensive Cancer Center, Buffalo, NY.
Leigh Anne StoutIndiana University School of Medicine, Indianapolis, IN.ORCID 0000-0002-6584-1818
Whitney MaxwellHuntsman Cancer Institute, University of Utah, Salt Lake City, UT.ORCID 0000-0002-7159-9239
Justine Cooper PickarskiMarkey Cancer Center, University of Kentucky, Lexington, KY.
Juvianee Estrada-VerasMurtha Cancer Center Research Program, Department of Surgery, Uniformed Service University of the Health Sciences, Bethesda, MD.ORCID 0000-0002-2372-0372
Bodour SalhiaDepartment of Translational Genomics, Norris Comprehensive Cancer Center, Keck School of Medicine of University of Southern California, Los Angeles, CA.ORCID 0000-0003-3843-3621
Lisen AxellDivision of Medical Oncology, University of Colorado Cancer Center, University of Colorado Anschutz Medical Campus, Aurora, CO.
Laura L HolmanDivision of Gynecologic Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK.
Mohamed H Abdel-RahmanDivision of Human Genetics, Departments of Ophthalmology and Internal Medicine, The Ohio State University, Columbus, OH.ORCID 0000-0002-9493-7894
Matthew D RingelDepartment of Molecular Medicine and Therapeutics, The Ohio State University College of Medicine, Columbus, OH.

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Daniel G. Stover · 1985 to 2026
$132.3M
Viral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Jon C.D. Houtman · 2000 to 2026
$70.0M
RCAN 1.4 metastasis suppressor in thyroid cancerR01CA240302 · NCI · OHIO STATE UNIVERSITY · PI RINGEL, MATTHEW D · 2020 to 2024
$2.2M
NCI NIH HHS P30 CA016058NCI NIH HHS P30 CA086862NCI NIH HHS R01 CA240302
6 · The paper itself

Abstract

purposeGermline likely pathogenic and pathogenic variants (LPV/PVs) in

methodsGermline exome data available for 19,315 patients with cancer from the Oncology Research Information Exchange Network (ORIEN) were assessed for

results

conclusionTo our knowledge, this study is the largest investigation of

Indexed as

Germ-Line MutationNeoplasmsTelomere-Binding ProteinsAdultAgedCohort StudiesFemaleHumansMaleMiddle AgedShelterin ComplexPOT1 protein, humanShelterin ComplexTelomere-Binding Proteins

Identifiers

PMID40632976
PMCPMC12243956

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.